An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Fludarabine; Prednisone; Vincristine
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms GAUDI
- Sponsors Roche
- 03 May 2019 Results of exposure-response analysis using data from six clinical trials in patients with CD20+ B-cell malignancies (CLL11, GADOLIN, GATHER, GAUDI, GAUGUIN, and GAUSS) published in the British Journal of Clinical Pharmacology
- 05 Dec 2014 Final results from maintenance phase presented at 56th American Society of Hematology Annual Meeting, according to a Genentech media release.
- 05 Dec 2014 Status changed from active, no longer recruiting to completed, according to Genentech media release.